Literature DB >> 11196167

Alterations of the double-strand break repair gene MRE11 in cancer.

T Fukuda1, T Sumiyoshi, M Takahashi, T Kataoka, T Asahara, H Inui, M Watatani, M Yasutomi, N Kamada, K Miyagawa.   

Abstract

MRE11 plays a role in DNA double-strand break repair. Hypomorphic mutations of MRE11 have been demonstrated in ataxia-telangiectasia (AT)-like disorder. ATM mutations play a causal role in AT and have been demonstrated in lymphoid malignancies in patients without AT histories. By analogy with the relationship of ATM to lymphoid malignancies, it is probable that alterations of MRE11 are associated with tumor formation. We performed a mutation analysis of MRE11 in 159 unselected primary tumors. Three missense mutations at conserved positions were found in breast and lymphoid tumors. Additionally, an aberrant transcript without genomic mutation was found in a breast tumor. These findings suggest an occasional role for MRE11 alterations in the development of primary tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11196167

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line.

Authors:  Qi Zhao; Otavia L Caballero; Samuel Levy; Brian J Stevenson; Christian Iseli; Sandro J de Souza; Pedro A Galante; Dana Busam; Margaret A Leversha; Kalyani Chadalavada; Yu-Hui Rogers; J Craig Venter; Andrew J G Simpson; Robert L Strausberg
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-30       Impact factor: 11.205

Review 2.  The cutting edges in DNA repair, licensing, and fidelity: DNA and RNA repair nucleases sculpt DNA to measure twice, cut once.

Authors:  Susan E Tsutakawa; Julien Lafrance-Vanasse; John A Tainer
Journal:  DNA Repair (Amst)       Date:  2014-04-19

Review 3.  Ataxia-telangiectasia and related diseases.

Authors:  Pierre-Olivier Frappart; Peter J McKinnon
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

4.  Next-Generation Sequencing Reveals a Nonsense Mutation (p.Arg364Ter) in MRE11A Gene in an Indian Patient with Familial Breast Cancer.

Authors:  Pratibha Sharma Bhai; Deepak Sharma; Renu Saxena; Ishwar C Verma
Journal:  Breast Care (Basel)       Date:  2017-03-21       Impact factor: 2.860

5.  Human MRE11 is inactivated in mismatch repair-deficient cancers.

Authors:  Giuseppe Giannini; Elisabetta Ristori; Fabio Cerignoli; Christian Rinaldi; Massimo Zani; Alessandra Viel; Laura Ottini; Marco Crescenzi; Stefano Martinotti; Margherita Bignami; Luigi Frati; Isabella Screpanti; Alberto Gulino
Journal:  EMBO Rep       Date:  2002-02-15       Impact factor: 8.807

6.  Deficient repair of particulate hexavalent chromium-induced DNA double strand breaks leads to neoplastic transformation.

Authors:  Hong Xie; Sandra S Wise; John P Wise
Journal:  Mutat Res       Date:  2007-10-09       Impact factor: 2.433

7.  Disease-associated MRE11 mutants impact ATM/ATR DNA damage signaling by distinct mechanisms.

Authors:  Joshua A Regal; Todd A Festerling; Jeffrey M Buis; David O Ferguson
Journal:  Hum Mol Genet       Date:  2013-08-02       Impact factor: 6.150

8.  Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy.

Authors:  Waleed M Abuzeid; Xiaoling Jiang; Guoli Shi; Hui Wang; David Paulson; Koji Araki; David Jungreis; James Carney; Bert W O'Malley; Daqing Li
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

9.  Role of the nuclease activity of Saccharomyces cerevisiae Mre11 in repair of DNA double-strand breaks in mitotic cells.

Authors:  L Kevin Lewis; Francesca Storici; Stephen Van Komen; Shanna Calero; Patrick Sung; Michael A Resnick
Journal:  Genetics       Date:  2004-04       Impact factor: 4.562

10.  Yeast-based screening of cancer mutations in the DNA damage response protein Mre11 demonstrates importance of conserved capping domain residues.

Authors:  Caitlin Harris; Jessica Savas; Sreerupa Ray; Erin K Shanle
Journal:  Mol Biol Rep       Date:  2021-06-01       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.